Grt-c903

Description

Grt-c903 is an investigational personalized cancer vaccine being studied in clinical trials. It is designed to target shared neoantigens, which are unique markers found on the surface of some cancer cells. These neoantigens arise from mutations in the cancer's DNA. The vaccine aims to teach the patient's immune system to recognize and attack these specific cancer cells. It is being investigated in combination with other immunotherapies (like checkpoint blockers) to boost the immune response. The trials are exploring the safety and effectiveness of this approach in patients with certain types of cancer, including colorectal cancer, particularly those with specific gene mutations like BRAF, EGFR, HER2, KRAS, or NRAS. It is currently in early-phase trials (Phase 1) to determine the right dose and how patients respond.

Mechanism of Action

Grt-c903 is a therapeutic vaccine. It works by presenting specific neoantigens (mutated peptides from the tumor) to the immune system. The goal is to stimulate the patient's T-cells to recognize and destroy cancer cells that display these neoantigens. It is designed to target 'shared' neoantigens, meaning these specific mutations and resulting neoantigens are found in multiple patients' tumors, allowing for a more standardized vaccine approach compared to fully individualized vaccines. It is used in combination with checkpoint blockade (like ipilimumab or nivolumab) to enhance the immune response.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials